Effect of metformin on the endometrium of obese, insulin-resistant wome
Not Applicable
- Conditions
- obese, insulin-resistant women
- Registration Number
- JPRN-UMIN000015470
- Lead Sponsor
- Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1.Prior medical history of chemical sensitivity to metformin 2.Women desiring to become pregnant during the study period 3.Serum creatinine level >1.0 mg/dL 4.History of lactic acidosis 5.Requiring dialysis 6.Shock, cardiac arrest, cardiac infarction, pulmonary thrombosis, or severe cardiovascular and/or lung damage 7.Ingestion of excessive amounts of alcohol 8.Liver dysfunction 9.History of thrombosis 10.Mental illness that may require antipsychotic therapy 11.Diabetes mellitus requiring medication 12.Concomitant malignancies 13.Ineligible, as determined by the physician-in-charge for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effect of metformin on phospho-ERK expression in the endometrium
- Secondary Outcome Measures
Name Time Method 1. To evaluate the effect of metformin on biomarker expression in the endometrium. Differences in Ki-67 and topoisomeraseIIa; expression will be assessed immunohistochemically.Phospho-AKT, phospho-AMPK, phospho-rpS6, cyclin D1, pRB, and p27 will be assessed using western blot analysis. 2. To evaluate the effect of metformin on serum biomarkers, such as insulin, IGF-1, and adipocytokines, such as leptin and adiponectin. 3. To evaluate the changes in BMI and insulin resistance after metformin treatment. 4. To evaluate the changes in the growth-stimulatory potential of sera after metformin treatment.